Dr. Marincola has pioneered research in tumor immunology by developing strategies for studying tumor-host interactions in the context of human genetic polymorphism and cancer heterogeneity. During his tenure as a Senior Staff Scientist with the NCI Surgery Branch, Dr. Marincola investigated the identification of the algorithm responsible for tumor rejection by immune cells particularly in the context of metastatic melanoma. Specifically, the focus of his research is the optimization of strategies to study clinical material during the conduct of clinical trials. Dr. Marincola is author of over 500 peer reviewed papers and is considered one of the world’s top experts in tumor immunotherapy.
Therapeutic Solutions International Inc (TSOI) Stock Research Links